Eastern Cooperative Oncology Group

东部肿瘤合作组

• 批准号: 8262137
• 负责人: GLENN J BUBLEY
• 金额: $ 9.54万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-12 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8262137
• 关键词: Angiogenesis Inhibition; Area; Breast; Cancer Center; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Commit; Data; Data Quality; Disease; Eastern Cooperative Oncology Group; Faculty; Funding; Grant; Hematologic Neoplasms; Home environment; Institution; Institutional Review Boards; Israel; Kidney; Laboratory Research; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Medical center; Multiple Myeloma; Ovarian; Participant; Patients; Prevention; Prostate; Protocols documentation; Recruitment Activity; Renal carcinoma; Research; Research Infrastructure; Research Personnel; Skin; Teaching Hospitals; Therapeutic; Therapy Clinical Trials; Translational Research; Vaccine Therapy; anticancer research; base; cytokine therapy; malignant breast neoplasm; medical schools; melanoma; oncology; programs; quality assurance

DESCRIPTION (provided by applicant): Beth Israel Deaconess Medical Center (BIDMC) is a major teaching hospital of Harvard Medical School. The BIDMC oncology faculty consists of an exceptional group of committed basic and clinical investigators. BIDMC is home to nationally recognized centers of expertise focused on breast cancer, melanoma, renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, hepatic cancer and hematologic malignancies. Areas of renowned scientific expertise include: vaccine and cytokine therapy, angiogenesis Inhibition and targeted therapy. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes ail Harvard Medical School affiliated Institutions. This arrangement enables the leveraging of scientific and clinical cancer research expertise across all Harvard institutions, enabling the creation of translational and clinical research entities. For example, since its founding, the DF/HCC has successfully competed for 8 SPORE grants (Breast, Skin, Kidney, Prostate, Ovarian, Myeloma and Lung), with BIDMC investigators being active participants in virtually all of these. Cancer clinical trials support is provided by a dedicated Cancer Clinical Trials Office (CCTO) which provides regulatory, administrative, educational and quality assurance support for 11 disease-based multi-disciplinary clinical research programs. BIDMC has been a main ECOG institution since 1997 and has been a main institution since 1998. Over the initial 11 years of funding, BIDMC investigators have consistently recruited 40-80 patients per year to therapeutic and prevention trials. To date, in 2009, BIDMC has accrued 30 patients to therapeutic trials. The BIDMC ECOG grant supports 3 affiliate institutions. BIDMC investigator scientific and administrative participation in ECOG activities, data quality, data delinquency rates and affiliate accrual have all steadily increased over the past funding period. With the transition of research protocols to DF/HCC IRB and the creation of CCTO infrastructure now complete, the BIDMC stands poised to enhance our laboratory and clinical research contributions and increase our participation in ECOG related activities.

描述（由申请人提供）：贝斯以色列女执事医疗中心（BIDMC）是哈佛医学院的主要教学医院。BIDMC肿瘤学系由一群杰出的基础和临床研究人员组成。BIDMC是国家认可的专业中心，专注于乳腺癌，黑色素瘤，肾癌，前列腺癌，卵巢癌，胰腺癌，肝癌和血液恶性肿瘤。著名的科学专长领域包括：疫苗和细胞因子治疗，血管生成抑制和靶向治疗。1999年，BIDMC参与了Dana-Farber/哈佛癌症中心（DF/HCC）的成立，该中心包括所有哈佛医学院附属机构。这种安排使所有哈佛机构能够利用科学和临床癌症研究专业知识，从而创建转化和临床研究实体。例如，自成立以来，DF/HCC已经成功地竞争了8个SPORE赠款（乳腺，皮肤，肾脏，前列腺，卵巢，骨髓瘤和肺），BIDMC研究人员几乎都是这些资助的积极参与者。癌症临床试验支持由专门的癌症临床试验办公室（CTO）提供，该办公室为11个基于疾病的多学科临床研究项目提供监管，行政，教育和质量保证支持。自1997年以来，BIDMC一直是ECOG的主要机构，自1998年以来一直是主要机构。在最初的11年资助中，BIDMC研究人员每年持续招募40-80名患者进行治疗和预防试验。到目前为止，2009年，BIDMC已经招募了30名患者进行治疗试验。BIDMC ECOG赠款支持3个附属机构。在过去的资助期间，BIDMC研究者在ECOG活动中的科学和行政参与、数据质量、数据拖欠率和附属机构应计费用均稳步增加。随着研究方案向DF/HCC IRB的过渡以及CTO基础设施的创建现已完成，BIDMC准备加强我们的实验室和临床研究贡献，并增加我们对ECOG相关活动的参与。